CNBX Pharmaceuticals Inc.
CNBX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CNBX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CNBX
CNBX Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company focused on developing RCC-33, a first-in-class therapy for colorectal cancer, with no revenue and a negative equity position as of May 2026.
Key risk: Zero cash position
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of May 31, 2026.
CNBX Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company focused on developing RCC-33, a first-in-class therapy for colorectal cancer, with no revenue and a negative equity position as of May 2026.
- CNBX is a pre-clinical-stage, platform technology biopharmaceutical company focused on oncology, with a current focus on colorectal cancer (CRC) [sec_mda · as of 2026-06-24].
- Its lead drug candidate, RCC-33, is a first-in-class therapy being developed for two settings: as a standalone neoadjuvant treatment and for refractory patients adjuvant to surgery [sec_mda · as of 2026-06-24].
- As of May 2026, the company reported cash and equivalents of $0.0M, total revenue of $0.0M, net income of -$0.2M, and shareholders' equity of -$2.5M [sec].
- The company had planned to launch a Phase I/II clinical study for RCC-33 in 2023, but no updated clinical trial initiation has been reported in recent filings [sec · filed 2022-02-18].
What works
- RCC-33 is positioned as a first-in-class therapy targeting significant unmet medical needs in colorectal cancer, with potential applications in both neoadjuvant and refractory settings [sec_mda · as of 2026-06-24].
- The company maintains a platform technology approach that could allow opportunistic expansion into other high-need oncology areas through acquisition, collaboration, or internal development [sec · filed 2022-02-18].
What to weigh
- The company is pre-clinical-stage with no approved products or revenue, and as of May 2026 had zero cash and negative shareholders' equity of -$2.5M, indicating severe financial constraints [sec].
- The planned Phase I/II clinical study for RCC-33, originally targeted for 2023, has not been reported as initiated in subsequent filings, suggesting development delays [sec · filed 2022-02-18].
- The company's accumulated deficit and ongoing net losses (net income -$0.2M as of May 2026) raise questions about its ability to fund future operations without additional capital [sec].
From the filings
Quoted directly from source documents.
CNBX is a pre-clinical-stage biopharmaceutical company focused on colorectal cancer with drug candidate RCC-33.
“We are a pre-clinical-stage, platform technology biopharmaceutical company which has developed proprietary innovative medicines in areas of significant unmet medical needs in oncology, with a current focus on colorectal cancer ("CRC"). Our drug candidate under development for colon cancer is RCC-33, a first-in-class therapy”
SEC MD&A · June 24, 2026
The company had planned to launch a Phase I/II clinical study in 2023.
“We are currently preparing to launch our human Phase I/II (a) clinical study in 2023, for the evaluation of our lead drug candidate RCC-33 for the treatment of colorectal cancer.”
SEC filings · February 18, 2022
Risks & what to watch (4)›
Key risks
- Zero cash position — As of May 2026, the company reported $0.0M in cash, severely limiting its ability to fund operations or clinical trials [sec].
- Negative shareholders' equity — Shareholders' equity was -$2.5M as of May 2026, indicating a net deficit and potential insolvency risk [sec].
- Clinical development delays — The planned Phase I/II study for RCC-33 in 2023 has not been reported as initiated, suggesting significant delays [sec · filed 2022-02-18].
- No revenue or approved products — The company has zero revenue and is pre-clinical-stage, with no path to near-term commercialization [sec].
What to watch
- Any updates on the initiation of the Phase I/II clinical trial for RCC-33, originally planned for 2023 [sec · filed 2022-02-18].
- The company's ability to secure additional financing given its zero cash position as of May 2026 [sec].
- Potential partnerships or collaborations to advance RCC-33 development, as the company's strategy includes working with partners [sec · filed 2022-02-18].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run CNBX Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CNBX Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
0.7 months
OCF -$48K · Net income -$154K
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Sep 2024Institutional holders
1
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| archer investment corp | 9 | $0 |
Frequently asked questions
What is the AI investment thesis for CNBX Pharmaceuticals Inc.?
CNBX Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company focused on developing RCC-33, a first-in-class therapy for colorectal cancer, with no revenue and a negative equity position as of May 2026.
Who is the CEO of CNBX Pharmaceuticals Inc.?
Mr. Eyal Barad is the chief executive officer of CNBX Pharmaceuticals Inc. (CNBX).
Where is CNBX Pharmaceuticals Inc. headquartered?
CNBX Pharmaceuticals Inc. (CNBX) is headquartered in Bethesda, MD, United States.
What therapeutic areas does CNBX Pharmaceuticals Inc. focus on?
CNBX Pharmaceuticals Inc. develops therapies across Oncology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.